AAVXF — Abivax S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1956827 ·
France
Last close
$139.00
Market Cap
$12.12B
52W High
$139.00
52W Low
$71.26
ADV30
27
Next earnings
2026-09-21
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -56,229,000 | -48,468,000 | 547,142,000 | 477,423,000 | 117,548,000 |
| Dec 2025 | 0 | — | -71,648,000 | -81,960,000 | 584,341,000 | 516,685,000 | 129,136,000 |
| Sep 2025 | 0 | — | -80,712,000 | -153,358,000 | 652,052,000 | 589,703,000 | 140,814,000 |
| Jun 2025 | 0 | — | -46,496,000 | -48,414,000 | 119,641,000 | 60,946,000 | 167,921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,130,000
Investing CF
$-8,193,000
Financing CF
$547,307,000
CapEx
$-243,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-4.56
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-738,482,000
Inventory
—
Receivables
$10,495,000
ST Investments
$13,698,000
EBIT TTM
$-302,711,000
Pretax Income TTM
$-330,254,000
Interest Exp TTM
$27,543,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,920,000
EBITDA
$-254,004,000
Free Cash Flow
$-114,471,872
Enterprise Value
$10,564,133,888
Total Cash
$491,552,000
Total Debt
$34,211,000
Shares Out
87,160,669
Trailing EPS
$-5.28
Book Value
$6.24
ROE
-157.1%
ROA
-44.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -246,056,000 | -336,102,000 | 584,341,000 | 129,136,000 | — | -161,129,000 |
| Dec 2024 | 0 | -172,984,000 | -176,242,000 | 205,228,000 | 164,644,000 | — | -154,072,000 |
| Dec 2023 | 0 | -127,377,000 | -147,740,000 | 327,062,000 | 131,052,000 | — | -97,130,000 |
| Dec 2022 | 0 | -51,205,000 | -60,740,000 | 75,544,000 | 68,355,000 | — | -53,936,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $11.92B | $84.65 | — |
| CORT | CORCEPT THERAPEUTICS INC | $12.38B | $114.49 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.60B | $60.02 | — |
| AXSM | Axsome Therapeutics, Inc. | $11.22B | $217.99 | — |
| ELAN | Elanco Animal Health Inc | $13.17B | $26.37 | — |
News headlines (Yahoo Finance, 1h cache)
AbbVie Q2 Earnings Call Highlights
2026-07-31 15:04 · Yahoo
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
2026-07-30 20:05 · Yahoo
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
2026-07-30 14:31 · Yahoo
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants
2026-07-29 07:00 · Yahoo
ABIVAX Société Anonyme (ENXTPA:ABVX) Adds Commercial Leaders, Is The Upside Already Priced In?
2026-07-26 08:07 · Yahoo
Abivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D Deal
2026-07-25 10:07 · Yahoo
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
2026-07-23 20:05 · Yahoo
Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
2026-07-16 07:07 · Yahoo
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
2026-07-10 13:55 · Yahoo
Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma
2026-07-10 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.